Loading...

Soligenix, Inc.

SNGXNASDAQ
Healthcare
Biotechnology
$2.98
$-0.13(-4.18%)

Soligenix, Inc. (SNGX) Financial Performance & Income Statement Overview

Explore the financials of Soligenix, Inc. (SNGX), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-85.78%
85.78%
Operating Income Growth
-22.62%
22.62%
Net Income Growth
-41.28%
41.28%
Operating Cash Flow Growth
2.33%
2.33%
Operating Margin
-454173.95%
454173.95%
Gross Margin
-67.81%
67.81%
Net Profit Margin
-271189.11%
271189.11%
ROE
-148.30%
148.30%
ROIC
-150.51%
150.51%

Soligenix, Inc. (SNGX) Income Statement & Financial Overview

Review Soligenix, Inc. SNGX income statement with detailed quarterly and annual figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$0.00$6352.00$0.00$2342.00
Cost of Revenue$0.00$1049.00$0.00$2342.00
Gross Profit$0.00$0.00$0.00-$1588.00
Gross Profit Ratio$0.00$0.00$0.00-$0.68
R&D Expenses$2.23M$2.66M$968689.00$499570.00
SG&A Expenses$1.08M$1.05M$896547.00$1.24M
Operating Expenses$3.31M$3.71M$1.86M$1.74M
Total Costs & Expenses$0.00$3.71M$1.86M$1.75M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$0.00$0.00$0.00$35925.00
Depreciation & Amortization$0.00$1049.00$1589.00$1588.00
EBITDA-$3.31M-$3.71M-$1.86M-$1.77M
EBITDA Ratio$0.00-$584.23$0.00-$757.86
Operating Income-$3.31M-$3.71M-$1.86M-$1.74M
Operating Income Ratio$0.00-$584.38$0.00-$744.95
Other Income/Expenses (Net)$0.00$316015.00$145855.00$100173.00
Income Before Tax$0.00-$3.40M-$1.72M-$1.61M
Income Before Tax Ratio$0.00-$534.63$0.00-$688.59
Income Tax Expense$0.00-$409000.00$0.00$31819.00
Net Income$0.00-$2.99M-$1.72M-$1.64M
Net Income Ratio$0.00-$470.25$0.00-$702.18
EPS-$1.06-$0.78-$0.78-$1.31
Diluted EPS-$1.06-$0.78-$0.78-$1.31
Weighted Avg Shares Outstanding$3.05M$2.51M$2.20M$1.26M
Weighted Avg Shares Outstanding (Diluted)$3.05M$2.51M$2.20M$1.26M

Over the last four quarters, Soligenix, Inc.'s revenue moved from $2342.00 in Q2 2024 to $0.00 in Q1 2025. Operating income in Q1 2025 was -$3.31M, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Soligenix, Inc. remained robust at -$3.31M, reflecting operational efficiency. Net income rose to $0.00, with an EPS of -$1.06. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;